Test Overview

Test Methodology

Electrochemiluminescence Immunoassay (ECLIA)

Test Usage

Used in diagnosis of hyperthyroidism and Graves' disease.

Reference Range*

< or = 1.75 IU/L. At a decision limit of 1.75 IU/L, this assay has 97% sensitivity and 99% specificity for detection of Graves' disease. In healthy individuals and in patients with thyroid disease without diagnosis of Graves' disease, the upper limit of anti-TSHR values are 1.22 IU/L and 1.58 IU/L, respectively (97.5th percentiles).

* Reference ranges may change over time. Please refer to the original patient report when evaluating results.

Test Details

Days Test Performed

Monday - Friday

Analytic Time

1 - 4 days

Soft Order Code


MiChart Code

Thyrotropin Receptor Antibody

Test Updated

Update Type: Specimen collection or handling and/or storage changed

Updated Date: 03/04/2020



Thyrotropin Binding Inhibitory Immunoglobulin
Thyroid Stimulating Immunoglobulin
Thyroid Stimulating Hormone Receptor Antibody
TSH Binding Inhibition Index
Thyrotropin-Binding Inhibition Index
TSH Receptor Antibody
Thyrotropin Receptor Ab

+ See More



Laboratory Reference

Mayo THYRO (81797)

Looking to Order a Test?

We’ve provided helpful links to make ordering easy.

Find a Requisition

All specimens should be accompanied by a requisition.

Submitting Specimens

Learn about how to properly label and where to ship specimens.

Order Kits and Supplies

MLabs provides all the supplies necessary for the collection of specimens.

Test FAQ

Visit our provider FAQ and learn about common questions to ordering tests.

Specimen Requirements

Offsite Collection Instructions

Collect specimen in a red top or SST tube. Centrifuge, aliquot serum into a plastic vial and refrigerate. This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference.


Yellow Top Tube

Normal Volume

1 mL serum

Minimum Volume

0.8 mL serum

Additional Information

Measures both Thyroid Stimulating Immunoglobulin (TSI) and Thyrotropin Binding Inhibitory Immunoglobulin (TBII), but does not provide information about function. The Thyrotropin Receptor Autoantibody (TRAB) Assay has utility in the differential diagnosis of Graves disease versus toxic nodular goiter. A low-positive TRAB (15-60) upon initial diagnosis is indicative of a high likelihood that a 6-18 month course of anti-thyroid drug medication will result in remission of Graves disease. Conversely, a high-positive TRAB (>80) upon initial diagnosis indicates a low likelihood of disease remission following anti-thyroid therapy. Studies show that 83% of patients with detectable receptor antibody activity (i.e., an elevated TRAB) at the end of a twelve month course of anti-thyroid drug therapy subsequently relapse. Non-elevated TRAB concentrations after twelve months of drug treatment predict remission in 89% of patients at 1 year and in 81% at 3 years after drug withdrawal. In the most current studies, the frequency of an elevated TRAB in patients with confirmed Graves disease ranges from 94-100%. Test sent to Mayo Medical Laboratories.

Billing Information

Fee Codes

CPT Code




Have More Billing Questions?

Explore our helpful billing resources:

Billing Resources

Billing FAQ